See what questions
a doctor would ask.
Cancer Research UK is sponsoring a large clinical trial which will aim to develop and market the chemotherapeutic agent RH1. RH1 is a cytotoxic prodrug which is triggered by the enzyme DT-diaphorase produced by tumors. Thus it is a targeted therapy. RH1 acts similarly to already existing chemotherapeutic agent Mitomycin C but is believed to be more effective.
Source: summary of medical news story as reported by Pharmalive
About: Cancer Research UK sponsors new cancer drug trial
Date: 16 December 2004
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City